• Stanmore Resources to acquire Moranbah South, boosting coal resources

    Two miners laughing and having fun while using smart phone during their coffee break.

    The Stanmore Resources Ltd (ASX: SMR) share price is in the spotlight after the company announced a $105 million deal to acquire 100% of the Moranbah South coal tenements, boosting its resource base with 724 million tonnes of measured and indicated coal.

    What did Stanmore Resources report?

    • Stanmore agreed to acquire all of Moranbah South from Exxaro for US$105 million.
    • The Moranbah South tenements contain 724 million tonnes of measured and indicated coal resources.
    • The deal is conditional on Exxaro acquiring Anglo American’s 50% joint venture stake, giving Exxaro full ownership ahead of sale to Stanmore.
    • The acquisition removes up to US$60 million in deferred and contingent payments for Stanmore’s Isaac Downs Extension project.
    • Stanmore will fund the acquisition from existing cash and liquidity, so no shareholder approval is required.

    What else do investors need to know?

    The Moranbah South tenements are strategically located next to Stanmore’s existing Eagle Downs and Isaac Plains Complex mines in Queensland’s Bowen Basin. The resources are considered to be high-quality, premium hard coking coal and may benefit from shared infrastructure if Eagle Downs is developed.

    This transaction is expected to add significant value across Stanmore’s portfolio by increasing resource scale and potentially lowering development costs. The deal also cancels significant future payment obligations tied to earlier agreements on the Isaac Downs Extension, making the economics more attractive.

    Completion is expected before the end of 2026, subject to Exxaro acquiring full ownership and meeting regulatory approvals including the Foreign Investment Review Board and ACCC. An independent resource report is planned after the deal closes.

    What did Stanmore Resources management say?

    Chief Executive Officer & Executive Director Marcelo Matos said:

    The acquisition of the Moranbah South tenements will represent a significant milestone for Stanmore’s development portfolio, increasing our resource base and strengthening the platform to deliver on our future growth aspirations. The tenements are strategically complementary to Stanmore’s neighbouring projects, particularly Eagle Downs and the Isaac Downs Extension.

    What’s next for Stanmore Resources?

    Stanmore has signalled its intent to commission an independent report on the newly acquired resources, aiming to update shareholders and the market once new technical and feasibility studies are complete. If the acquisition closes as planned, Moranbah South could provide long-term synergies to future mining operations and development options.

    The company remains focused on strategic growth from its expanded portfolio and delivering increased value for investors as integration and further exploration proceeds.

    Stanmore Resources share price snapshot

    Over the past 12 months, Stanmore Resources shares have risen 64%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

    View Original Announcement

    The post Stanmore Resources to acquire Moranbah South, boosting coal resources appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Stanmore Resources right now?

    Before you buy Stanmore Resources shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Stanmore Resources wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

  • Could this ASX healthcare stock really be set to rise 400%? Morgans thinks so 

    Doctor with stethoscope holding a tablet and smiling.

    ASX healthcare stock Saluda Medical Inc (ASX: SLD) has been drawing significant attention from brokers in recent weeks. 

    The growth stock is a commercial-stage medical device company. It is focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. 

    The company’s first product, the Evoke System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy.

    It hasn’t been smooth sailing for this ASX healthcare stock in recent times. Its share price has tumbled 71% year to date. 

    However, Morgans sees major upside over the next 12 months. 

    Here’s the latest from the broker. 

    Solid FY26 for ASX healthcare stock

    In a note out of Morgans this week, the broker said FY26 finished strong and mostly ahead of prospectus, but the more important development is showing greater visibility on the path to operating leverage. 

    FY27 guidance calls for 25% to 35% revenue growth, 50% to 52% gross margin, and a US$95 to $101 million adjusted EBITDA loss, with management expecting 90% of incremental gross profit to translate into adjusted EBITDA improvement. 

    Salesforce maturation is key, with 161 US reps at FY26 year-end, 55% fully trained and the majority of the remaining cohort expected to come online in 1HFY27. Growth looks set to come from higher productivity rather than simply adding headcount, with c30% of territories operating below a 40% fully loaded rep-cost/revenue threshold, providing evidence that the territory economics can work. 

    We see FY27 as the first meaningful test of the model’s scalability, with higher physician utilisation, maturing territories and the CAP24 paddle lead providing potential upside to guidance. We adjust FY27-28 forecasts, with our DCF-based target price moving to A$2.17 (from A$2.94). SPECULATIVE BUY maintained.

    This ASX healthcare stock closed trading yesterday at just over 41 cents per share. 

    The target from Morgans indicates an upside potential of 422%. 

    Other brokers also bullish

    Morgans isn’t alone in its outlook for this ASX healthcare stock. 

    The team at Bell Potter recently updated their price target to $1.60. 

    This indicates an upside of over 285%. 

    Speaking on the lofty target, the broker said: 

    SLD’s US commercial execution continues to impress and accelerated considerably in recent quarters (34% US growth in Q3, 45% in Q4). Tailwinds continue to build following FDA approval of SLD’s paddle lead in June and ~40% of the current sales force expected to complete training in FY27 and contribute to revenue generation. Real-world data continues to affirm Evoke’s value proposition: greater efficacy durability means fewer reprogramming requirements and therefore greater revenue/rep compared to conventional devices.

    The post Could this ASX healthcare stock really be set to rise 400%? Morgans thinks so  appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Saluda Medical right now?

    Before you buy Saluda Medical shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Saluda Medical wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Up 83%! 4 reasons I’d still buy this $8 billion ASX 200 gold stock today

    Stacked gold bricks.

    The S&P/ASX 200 Index (ASX: XJO) has gained 3.2% over 12 months, but this ASX 200 gold stock has left those gains wanting.

    The surging gold miner in question is Greatland Resources Ltd (ASX: GGP).

    In late-afternoon trade on Thursday, Greatland Resources shares were trading for $11.33 apiece. That sees the share price up a whopping 83.1% since this time last year. And it gives the Aussie gold miner a market cap of just over $7.6 billion.

    Greatland has benefited from both the strong gold price and the fast-rising copper price, with exposure to both through its Telfer and Havieron gold-copper mines in Western Australia.

    And the ASX 200 gold stock has hardly been sitting idle.

    Here’s why it still looks like a compelling buy today.

    Why this ASX 200 gold stock could keep charging higher

    MPC Markets’ Jonathan Tacadena recently analysed the outlook for Greatland’s surging shares (courtesy of The Bull).

    “GGP is a gold and copper producer,” he noted.

    Citing the first reason he issued a buy recommendation on the ASX 200 gold stock, Tacadena said, “The company produced 329,000 ounces of gold in full year 2026, comfortably beating guidance.”

    And Greatland is keeping a lid on its production costs.

    “All in sustaining costs [AISC] were also below guidance,” Tacadena said.

    For FY 2026, Greatland Resources reported an AISC of $2,179 per ounce of gold produced.

    Then there’s the miner’s admirable balance sheet.

    “It held cash of $1.289 billion at June 30 and had no debt,” Tacadena noted.

    As for the fourth reason the ASX 200 gold stock still looks like a good buy today, he concluded:

    It has full upside exposure to the gold price via put options. A reserve upgrade at the Telfer mine in Western Australia is also encouraging. The company is enjoying favourable momentum.

    What’s the latest from Greatland Resources?

    Greatland Resources announced its FY 2026 results on 27 August, the first full year that it owned the Telfer gold mine.

    The company reported revenue of $2.26 billion from sales of 326,859 ounces of gold and 14,730 tonnes of copper, with free cash flow of $737 million, soaring 413% from FY 2025.

    On the bottom line, the ASX 200 gold stock achieved a net profit after tax (NPAT) of $862 million, up 156% year on year.

    Commenting on the strong results, Greatland managing director Shaun Day said:

    Our first full financial year of Telfer under our ownership delivered exceptional operating results, driven by significant productivity improvements in our open pit and underground mines, and an excellent performance in our processing operations.

    The post Up 83%! 4 reasons I’d still buy this $8 billion ASX 200 gold stock today appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Greatland Resources right now?

    Before you buy Greatland Resources shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Greatland Resources wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sorry, but nothing was found. Please try a search with different keywords.